Source: Investing.com ↗

Novartis initiates phase 2 study of MRT-6160 for Sjögren’s disease

|

Translation unavailable. Please try again.

Original report

Read the original report on Investing.com ↗

Recommended markets

No specific asset was identified in this report; browse live USDT reference pairs.

Browse markets →

USDC/USDT

$1.00

-0.02%

BTC/USDT

$85,855.16

-0.29%

ETH/USDT

$2,733.82

-0.51%

ZEC/USDT

$1,624.13

+7.96%

XRP/USDT

$1.59

+3.75%